[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gene-expression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gene-expression":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644813","dietary-macronutrients-and-gut-microbiota-inflammation-and-metabolic-markers-100644813",false,"NCT07672691","Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers","Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.","DIETMICRO","Inclusion Criteria:\n\nIn addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:\n\nBMI not exceeding 40kg\u002Fm²\n\nHabitual mixed diet prior to study enrollment\n\nNormal blood pressure\n\n* Exclusion Criteria:\n\nPoprawiłem już \\*\\*Exclusion Criteria\\*\\* w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:\n\n\\*\\*\\* \\*\\*Exclusion Criteria:\\*\\*\n\n* Use of medications regulating \\*\\*glucose levels\\*\\* (e.g., metformin) or \\*\\*blood lipids\\*\\* (e.g., \\*\\*statins\\*\\*)\n* \\*\\*Hypertension\\*\\* or pharmacological treatment for hypertension\n* Diagnosed \\*\\*gastrointestinal disorders\\*\\*, including:\n* Gastric and duodenal ulcers\n* \\*\\*Irritable bowel syndrome (IBS)\\*\\*\n* \\*\\*Ulcerative colitis\\*\\*\n* \\*\\*Celiac disease\\*\\*\n* Chronic use of medications such as:\n* \\*\\*Mesalazine\\*\\*\n* \\*\\*Corticosteroids\\*\\*\n* \\*\\*Statins\\*\\*\n* \\*\\*Proton pump inhibitors (PPI)\\*\\*\n* \\*\\*Non-steroidal anti-inflammatory drugs (NSAIDs)\\*\\*\n* \\*\\*Anticonceptional medications\\*\\*\n* \\*\\*Any supplements\\*\\*\n* \\*\\*Alcohol consumption\\*\\* \\> 2 times\u002Fweek with \\> 15 g alcohol per occasion (approximately 15 g alcohol = 330 mL beer, 150 mL dry red wine, or 50 mL vodka)\n* \\*\\*Smoking cigarettes\\*\\*\n* Following a \\*\\*ketogenic diet\\*\\* or \\*\\*vegetarian diet\\*\\* within \\*\\*1 month\\*\\* prior to study enrollment",true,"ALL","18 Years","60 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","Poniżej znajduje się bardziej płynna i mniej powtarzalna wersja tekstu:\n\nThis 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.\n\nParticipants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.\n\nThe study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.\n\nBy comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.\n\nTa wersja eliminuje powtórzenia (\"diet\", \"study\", \"monitor\", \"effects\"), jest bardziej naturalna stylistycznie i odpowiada standardowi językowemu publikacji w czasopismach z zakresu żywienia i medycyny.",[29,30,31,32],"Nutrition","Ketogenic Diet","Gene Expression","Diet",[34,35,36,37,38,39],"ketogenic diet","gene expression","transcriptomics","biochemical parameters","stool microbiome","ketone bodies","RECRUITING","2026-07-01",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2024-09-02",{"date":48,"type":23},"2028-12-30",{"name":50,"class":51},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100610230","ellacor-micro-coring-technology-in-fitzpatrick-skin-types-i-vi-including-patients-receiving-glucagon-like-peptide-1-receptor-agonists-100610230","NCT07224880","Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists","Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series","Inclusion Criteria:\n\n1. Male and female adult, between the ages of 30 and 65\n2. Fitzpatrick Skin Type I-VI\n3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.\n4. Have moderate to extreme abdominal laxity according to Stokes Scale (i.e., score of 2-4 on a scale of 0-4).\n5. Willingness to sign Informed Consent Form\n\nExclusion Criteria:\n\n1. Pregnant women or nursing mothers\n2. Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area\n3. Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine\n4. Patients with a history or presence of any clinically significant bleeding disorder\n5. Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules\u002Fnodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus\n6. Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)\n7. Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days\n8. Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area\n9. Patients with have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old\n10. Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive\u002Finvasive skin treatment in the treatment area during the previous six (6) months\n11. Patients with scars less than six (6) months old in the treatment area","30 Years","65 Years",{"count":63,"type":23},10,"OBSERVATIONAL","The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity",[67,31,68],"glp1 Agonist","Skin Laxity",[70,71,72],"ellacor","GLP-1","weight loss","2025-12-30",{"date":75,"type":44},"2025-12-31",{"date":77,"type":44},"2025-10-14",{"date":79,"type":23},"2026-02-28",{"name":81,"class":82},"Cytrellis Biosystems, Inc.","INDUSTRY",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":93,"conditions":94,"keywords":104,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":83},"100581156","host-response-to-infection-by-direct-analysis-of-leukocyte-single-cell-type-gene-expressiontranscript-abundance-direct-ls-ta-a-prospective-study-will-evaluate-the-performance-of-direct-ls-ta-in-triage-febrile-patients-into-major-categories-of-infections-viral-bacterial-or-active-tuberculosis-100581156","NCT06846645","Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression\u002Ftranscript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.","Peripheral Blood Single Cell-type Expression Profile of Interferon-stimulated and Other Biomarker Genes for Triage of Febrile Patients","Inclusion Criteria:\n\n* Adult patients with fever of acute onset which is defined by a raised body temperature.\n* Patient should understand Chinese word to give informed consent.\n\nExclusion Criteria:\n\n* Patients with a history of any immunodeficiency or immunocompromised condition. Patients received steriod or other immunotherapy.","80 Years",{"count":22,"type":23},"Febrile illness is a common condition and it is crucial to have an early triage of patients according to various aetiologies to enable appropriate treatment. Currently, most screening\u002Fdiagnostic tests target the detection of pathogens, while only a few assays aim to understand the host response, and they are mostly based on a measurement of serum proteins (e.g. CRP or procalcitonin).\n\nRecently, blood transcriptome has been explored to differentiate bacterial and viral infections. However, gene expression in blood represents a composite score of gene expression of all the component cell-types present in the sample. Here, we propose to develop a rapid test that can determine gene expressions of a specified single cell type in peripheral blood (e.g., monocytes or granulocytes) as a host response biomarker to differentiate three major categories of infections that are bacterial, viral, and tuberculosis The assay is called Direct Leukocyte Single cell-type transcript abundance (TA) assay (DIRECT LS-TA) as it can directly determine the gene expression of a specified single cell-type among various other leukocyte populations directly in a peripheral blood sample. Such results signify the nature of host response according to 3 or more axes (Type I or Type II interferon signaling response or pro-inflammatory cytokine signaling) And it can be used to indicate the type of underlying infection (viral, bacterial, or active tuberculosis).",[95,96,31,97,98,99,100,101,102,103],"Single Cell Sequencing Technology","Gene Expression Profiling","Infection","Viral Diseases","Bacterial Diseases","Active Tuberculosis","Host Defense Mechanisms","Host Microbial Interactions","Transcriptome",[105,106,107,108,109,110,111,112],"host response","transcriptome","single cell-type gene expression","single cell RNA","triage","fever","febrile patient","Direct LS-TA","NOT_YET_RECRUITING","2025-02-27",{"date":116,"type":44},"2025-03-03",{"date":118,"type":23},"2025-02",{"date":120,"type":23},"2028-12",{"name":122,"class":51},"Chinese University of Hong Kong"]